Hansoh Pharmaceutical Group Company Limited
HKSE: 3692.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Huijuan Zhong
- Employees
- 8,989
- Headquarters
- Lianyungang, China
- IPO year
- 2019
- Market cap
- HK$219.7B
- Website
- https://www.hspharm.com
Loading 3692…
Loading profile data…Frequently asked questions about 3692
What does Hansoh Pharmaceutical Group Company Limited (3692.HK) do?
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. It...
Where does 3692.HK trade?
Hansoh Pharmaceutical Group Company Limited (3692.HK) trades on the Hong Kong Stock Exchange.
What sector is 3692.HK in?
Hansoh Pharmaceutical Group Company Limited (3692.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hansoh Pharmaceutical Group Company Limited?
Huijuan Zhong is the chief executive officer of Hansoh Pharmaceutical Group Company Limited (3692.HK).
Where is Hansoh Pharmaceutical Group Company Limited headquartered?
Hansoh Pharmaceutical Group Company Limited is headquartered in China.
Does 3692.HK pay a dividend?
Yes — Hansoh Pharmaceutical Group Company Limited (3692.HK) paid a trailing twelve-month dividend of HKD 0.37 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 3692.HK go public?
Hansoh Pharmaceutical Group Company Limited (3692.HK) completed its initial public offering in 2019.